RUO materials are not subject to FDA pre-market approval for human administration, cannot be used as drug ingredients in compounding, and are not intended for diagnostic, therapeutic, or veterinary use
Standard Dosing Ranges The most extensively studied dosing protocols for subcutaneous administration include: Research-Based Dosing Protocols Beginner/Conservative Protocol: Dose: 250-300 mcg once daily Duration: 4-8 weeks initial assessment period Rationale: Allows tolerance assessment and response evaluation at lower end of therapeutic range Standard Protocol: Dose: 300-500 mcg once daily Duration: 12-24 weeks based on clinical trials Rationale: Most commonly studied range in human research with optimal benefit-to-safety ratio Advanced Protocol: Dose: 500 mcg-1 mg once daily Duration: 12-24 weeks under close medical monitoring Rationale: Upper clinical range
Sarvan, E
Clin Endocrinol 83:593595 Ewert A, Leifheit-Nestler M, Hohenfellner K, Bscher A, Kemper MJ, Oh J, Billing H, Thumfart J, Stangl G, Baur AC, Fller M, Feger M, Weber LT, Acham-Roschitz B, Arbeiter K, Tnshoff B, Zivicnjak M, Haffner D (2020) Bone and mineral metabolism in children with nephropathic cystinosis compared with other CKD entities
